Real-World Progression-Free Survival and Healthcare Resource Utilization Associated with Daratumumab Use in Transplant-Ineligible Multiple Myeloma Patients in Italy. [PDF]
Perrone V +24 more
europepmc +1 more source
RE: Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival [PDF]
Wen-zhuo, He, Liang-ping, Xia
openaire +2 more sources
Dapagliflozin prevents methylglyoxal‐induced retinal cell death in ARPE‐19 cells
Diabetic macular oedema is a diabetes complication of the eye, which may lead to permanent blindness. ARPE‐19 are human retinal cells used to study retinal diseases and potential therapeutics. Methylglyoxal is a compound increased in uncontrolled diabetes due to elevated blood glucose.
Naina Trivedi +7 more
wiley +1 more source
Prognostic impact of sarcopenia on 5-year overall and progression-free survival in lung cancer patients: a prospective cohort study. [PDF]
Zhao T, Li XQ, Shi Z, Zhang CB, Zhu YG.
europepmc +1 more source
We first identified functional murine mitochondrial N‐formyl peptides (MT‐FPs) and investigated their effects on the in vitro myeloid‐derived suppressor cell (MDSC) generation from bone marrow cells. We demonstrated that MT‐FPs acted directly on bone marrow cells to promote MDSC generation and modulated the polymorphonuclear (PMN)‐MDSC/monocyte (M ...
Miyako Ozawa +2 more
wiley +1 more source
Impact of Achieving Progression-Free Survival 24 on Subsequent Overall Survival in Diffuse Large B-Cell Lymphoma Patients. [PDF]
Fujimoto A +11 more
europepmc +1 more source
D3.1.1 Progression Free Survival (PFS) read out
D311 Progression Free Survival PFS read ...
openaire +1 more source
ERα splice variant ERα∆7 lacks the C‐terminus, and its expression may change phenotypes of breast cancers. Our results showed that ERα∆7 is found in the luminal A subtype, and elevated ERα∆7 levels are linked to improved cell survival with lower proliferation and migration.
Long Wai Tsui +10 more
wiley +1 more source
Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma. [PDF]
Mian H +7 more
europepmc +1 more source
Matrix metalloproteinase‐9 (MMP9) drives ovarian cancer progression. Using MMP9‐null cells (M9‐KO) created from ovarian cancer cells, we found MMP9 loss did not block Epidermal Growth Factor (EGF)‐driven E‐cadherin dissolution or EMT but delayed and reduced EGF‐driven membrane protrusions. Transient MMP9 re‐expression drove membrane protrusion.
Claire Strauel +8 more
wiley +1 more source

